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ORIGINAL ARTICLE

The CNDR: Collaborating to Translate
New Therapies for Canadians

Lawrence Korngut, Craig Campbell, Megan Johnston, Timothy Benstead, Angela
Genge, Alex MacKenzie, Anna McCormick, Douglas Biggar, Pierre Bourque,
Hannah Briemberg, Colleen O’Connell, Suzan Dojeiji, Joseph Dooley, Ian
Grant, Gillian Hogan, Wendy Johnston, Sanjay Kalra, Hans D. Katzberg, Jean
K. Mah, Laura McAdam, Hugh J. McMillan, Michel Melanson, Kathryn Selby,
Christen Shoesmith, Garth Smith, Shannon L. Venance, Joy Wee on behalf of the
CNDR Investigator Network*
ABSTRACT: Background: Patient registries represent an important method of organizing “real world” patient information for clinical
and research purposes. Registries can facilitate clinical trial planning and recruitment and are particularly useful in this regard for
uncommon and rare diseases. Neuromuscular diseases (NMDs) are individually rare but in aggregate have a significant prevalence. In
Canada, information on NMDs is lacking. Barriers to performing Canadian multicentre NMD research exist which can be overcome by
a comprehensive and collaborative NMD registry. Methods: We describe the objectives, design, feasibility and initial recruitment results
for the Canadian Neuromuscular Disease Registry (CNDR). Results: The CNDR is a clinic-based registry which launched nationally in
June 2011, incorporates paediatric and adult neuromuscular clinics in British Columbia, Alberta, Ontario, Quebec, New Brunswick and
Nova Scotia and, as of December 2012, has recruited 1161 patients from 12 provinces and territories. Complete medical datasets have
been captured on 460 “index disease” patients. Another 618 “non-index” patients have been recruited with capture of physicianconfirmed diagnosis and contact information. We have demonstrated the feasibility of blended clinic and central office-based
recruitment. “Index disease” patients recruited at the time of writing include 253 with Duchenne and Becker muscular dystrophy, 161
with myotonic dystrophy, and 71 with ALS. Conclusions: The CNDR is a new nationwide registry of patients with NMDs that
represents an important advance in Canadian neuromuscular disease research capacity. It provides an innovative platform for organizing
patient information to facilitate clinical research and to expedite translation of recent laboratory findings into human studies.
RÉSUMÉ: Le RCMN : collaborer pour procurer de nouveaux traitements aux Canadiens. Contexte : Un registre de patients est une façon très
avantageuse d’organiser l’information concrète au sujet de patients à des fins cliniques ou de recherche. Les registres peuvent faciliter la planification
d’essais cliniques et le recrutement et sont particulièrement utiles à cet égard quand il s’agit de maladies rares. Les maladies neuromusculaires (MNM)
considérées individuellement sont des maladies rares mais elles ont une prévalence non négligeable si elles sont regroupées. Au Canada, on manque
d’informations sur les MNM. Il existe des obstacles à la réalisation de recherches multicentriques sur les MNM au Canada. Ces obstacles peuvent être
surmontés par l’établissement d’un registre détaillé à des fins de collaboration sur les MNM. Méthode : Nous décrivons les objectifs, le plan, la
faisabilité et les résultats du recrutement initial du Registre canadien des maladies neuromusculaires. Résultats : Le RCMN est un registre basé sur la
clinique qui a été inauguré à travers le Canada en juin 2011. Il inclut des cliniques neuromusculaires pédiatriques et adultes et inclut des patients de
Colombie-Britannique, d’Alberta, de l’Ontario, du Québec, du Nouveau-Brunswick et de la Nouvelle-Écosse. En décembre 2012, 1 161 patients de 12
provinces et territoires avaient été recrutés. Des données médicales complètes sur 460 « propositi » atteints de MNM répertoriées au fichier y ont été
inscrits. Six cent dix-huit autres patients qui ne sont pas des « propositi » ont été recrutés et leurs coordonnées ainsi qu’un diagnostic confirmé par un
médecin ont été inscrits au registre. Nous avons démontré la faisabilité d’un recrutement mixte soit à partir de cliniques et également d’un bureau central.
Les patients atteints de maladies répertoriées au registre à ce jour incluent 253 patients atteints de dystrophie musculaire de Duchenne ou de Becker,
161 patients atteints de dystrophie myotonique et 71 patients atteints de sclérose latérale amyotrophique. Conclusions : Le RCMN est un nouveau
registre national de patients atteints de MNM, un progrès important en matière de capacité de recherche sur les maladies neuromusculaires au Canada.
Il fournit une plateforme innovatrice pour l’organisation de l’information concernant les patients dans le but de faciliter la recherche clinique et
d’accélérer le transfert des connaissances acquises récemment en laboratoire vers les études chez l’humain.

Can J Neurol Sci. 2013; 40: 698-704
From the Canadian Neuromuscular Disease Registry Investigator Network (see Appendix I for affiliations of its investigators).*
RECEIVED MARCH 11, 2013. FINAL REVISIONS SUBMITTED APRIL 2, 2013.
Correspondence to: Lawrence Korngut, Clinical Neurosciences, 480060, 4th Floor Administration, South Health Campus, 4448 Front Street SE, Calgary, Alberta,
T3M 1M4, Canada. Email: lawrence.korngut@albertahealthservices.ca.

698
https://doi.org/10.1017/S0317167100014943 Published online by Cambridge University Press

LE JOURNAL CANADIEN DES SCIENCES NEUROLOGIQUES

The spectrum of neuromuscular disease (NMD) includes
conditions that result primarily in muscle weakness and/or
sensory deficits from nerve, muscle, or neuromuscular junction
impairment often including central nervous system dysfunction.
NMDs encompass a broad spectrum of etiologies from inherited
(the muscular dystrophies) to inflammatory (Guillain-Barré
syndrome), through to degenerative amyotrophic lateral sclerosis
(ALS). The individual NMDs are rare but as a group are not
uncommon. Moreover, common conditions such as diabetes
mellitus result in secondary NMDs (e.g. diabetic polyneuropathy) that is observed in upwards of 1-2% of all people1,2
while rarer inherited NMDs collectively occur with an estimated
prevalence of 1 per 29003. ALS demonstrates a low incidence of
1-2 per 100,000/year, but the cumulative lifetime risk has been
shown to be as high as 1 in 3384. The majority of patients with
NMDs are diagnosed and followed in dedicated regional
neuromuscular clinics (NMCs), a reflection of the expertise
required in their diagnosis and management.
International efforts to organize NMD patient populations
have been successful in enhancing collaborative research efforts
and surmounting geographic barriers to clinical study planning
and recruitment5. Canadian NMD physicians and scientists have
recently been collaborating through efforts such as the Canadian
Paediatric Neuromuscular Group and the Canadian ALS
Network, to improve care and develop therapies for Canadians
with NMDs. However, there has been a lack of infrastructure to
support multi-centre collection and curation of patient
information. Enhanced collaboration through the development of
shared research tools and patient registries is expected to attract
international clinical trials, thereby, improving access to novel
therapies-in-development for Canadians6,7.
Patient registries represent an important method of collecting
and organizing patient information for clinical and research
purposes. Patient registries complement clinical trials by
providing data that is highly generalizable or “real world.”
Registries can also provide accurate estimates of disease
incidence and prevalence. The Northern Ireland Motor Neurone
Disease project recently demonstrated a 99% completeness of
ALS case ascertainment using rigorous capture-recapture
methodology8. Registries can also reduce clinical study
recruitment time, effort and cost through direct recruitment of
registry participants potentially making countries with
established registries more attractive for clinical trials9.
Development of a Canadian NMD registry is timely as in
recent years a clearer understanding of disease mechanisms for
several NMDs has emerged. Major advances in Duchenne
(DMD), myotonic (DM), facioscapulohumeral (FSHD)
muscular dystrophies and amyotrophic lateral sclerosis (ALS)
have accelerated therapy development of novel molecular
targets10-13. Specific causative genetic mutations have been
targeted in Duchenne muscular dystrophy (DMD) with
restoration of dystrophin expression. Both nonsense mutation
read-through agents (eg. Ataluren, clinicaltrials.gov
NCT01009294) and antisense oligonucleotide-mediated exon
skipping have promising DMD human trials underway14,15.
Translation of laboratory findings into clinical therapeutic
applications has recently resulted in a new therapy for Pompe
disease16.
In this paper we discuss the objectives, design, feasibility, and
initial recruitment results of the CNDR.
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METHODS

Objectives

The CNDR aims to improve the future for Canadians with
NMD through the enablement and support of research into
potential treatments. Secondary objectives include enhancing the
understanding of NMD epidemiology, addressing variations in
management, and facilitating clinical knowledge translation.

Neuromuscular Clinic Selection

Paediatric and adult neuromuscular clinics across Canada
were invited to participate in the CNDR. Selection criteria
included: (1) demonstrated clinical focus on patients with NMD,
(2) academic affiliation, and (3) interest in participating.

Registry Design

The CNDR consists of affiliated regional co-investigators
and their respective neuromuscular clinics acting as clinical data
collection centres. It is administered and supported centrally
through the national office at the University of Calgary. Each
clinic seeks local ethics approval utilizing a standardized ethics
package. The CNDR National Office conducts a site initiation
visit including protocol review followed by CNDR software
desk-side training prior to initiation of enrollment.

Organizational Structure and Scientific Expertise

Medical and scientific expertise is provided by the CNDR
Advisory Committee (CNDRAC). The CNDR Sponsors
Committee (CNDRSC) is comprised of sponsors contributing
significant funding to the CNDR.
A Disease Working Group (DWG) is formed for each index
disease and is comprised of medical, research, basic science, and
genetics experts led by a committee chair who serves on the
CNDRAC. Disease Working Groups meet annually to review
dataset components to maintain relevance of data collected.
These experts develop the data reference manuals covering the
specifications for each disease dataset.

Patient Eligibility and Consent

All Canadian residents diagnosed with a neuromuscular
disease (NMD) and providing voluntary, informed consent are
eligible for registration with the CNDR. The spectrum of NMDs
eligible for the CNDR include those defined by the World
Federation of Neurology classification of neuromuscular
diseases17. Patients may provide additional consent for data
transfer to the Translational Research in Europe – Assessment
and Treatment of Neuromuscular Diseases (TREAT-NMD)
Global Registry5, notification of research studies they may be
eligible for, and for updating of their medical information on
future routine visits to the clinic.
Patient Recruitment

The CNDR employs an innovative blended recruitment
model enrolling subjects during routine visits at participating
CNDR-affiliated NMCs in combination with direct selfregistration through the CNDR National Office for patients
unable to attend affiliated clinics. The CNDR public website
(http://www.cndr.org) provides information and facilitates
699
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recruitment through contact between interested patients and
CNDR National Office staff. Importantly, any Canadian
physician can refer a patient to the CNDR for enrollment either
through completion of forms available through the National
Office or patient self-referral.

Patient Data Collection and Management

Patient data is collected prospectively at routine clinic visits
through completion of data collection forms by the attending
physicians and trained data entry staff reviewing information on
the patient chart. “Index” NMDs have more extensive datasets
derived by national and international expert consensus18. “Nonindex” NMD datasets collect only contact information and a
physician-confirmed diagnosis. The CNDR National Office
monitors dataset item quality and completion rates ensuring
capture of high-quality data. Data entry and quality monitoring is
summarized in Appendix 2.
Access to CNDR Data

A key component of registry effectiveness is availability of
data for the planning and execution of research. The CNDR has
taken a novel approach enabling the release of data in two
categories. All academic institution-affiliated investigators may
submit research proposals requesting release of CNDR data.
Following ethics review board approval at the requesting
investigator’s institution, research proposals are examined by a
peer review committee consisting of DWG and CNDRAC
members as well as other internal or external experts appropriate
to the nature of the research. Research proposals are scored
based on their scientific merit as well as their benefit to the
patient population. Following approval, the CNDR National
Office provides a customized de-identified dataset tailored to the
research project needs.
The second category of data requested from the CNDR is a
“statistical data request”. These requests may be submitted by
any third parties (i.e. pharmaceutical companies) planning
studies that have not yet received ethics approval and result in
provision of general CNDR statistics to facilitate study planning.
Balancing the need for data accessibility is subject privacy
and confidentiality. Strict measures are in place to ensure that
appropriate levels of de-identification are maintained to prevent
identification of subjects at any time. Release of identified data
is prohibited.

Study Recruitment Through the CNDR

The CNDR can also be used to facilitate study recruitment
both locally and internationally. Researchers can submit an
ethics-approved protocol for CNDR peer review. Upon research
protocol and recruitment material approval the database is
scanned for eligible patients. Eligible patients receive a mail-out
with information regarding their eligibility for the study and
contact information for the study investigators if they should
choose to participate. The CNDR does not recruit patients
directly for studies.

The CNDR as a Clinical Tool

The CNDR provides readily accessible patient data to local
sites that has been useful to participating physicians and health
700
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care teams. CNDR index disease dataset requirements encourage
review of specific patient information at routine appointments.
Future studies will determine whether access to a standardized
national dataset results in clinical benefits for participating
patients and physicians and whether adherence to best practice
standards is facilitated.

Recruitment Feasibility

Two case studies were undertaken during 2011 to assess the
feasibility of patient recruitment through the CNDR clinic-based
model. The first case study consisted of a single clinic
enrollment model assessing ALS patient recruitment. Eligible
patients were identified through ALS clinic lists and chart
review. Between March 1, 2011 and February 29, 2012, ALS
patients meeting at least El-Escorial criteria of Possible ALS
were prospectively recruited at the Calgary ALS Clinic. It was
considered that successful recruitment of 70% of known ALS
patients in the clinic over the one year interval would be
considered effective recruitment based on approximate patient
return-to-clinic intervals and physician availability for
recruitment during clinic visits.
A second case study was undertaken from March 1, 2011
through December 31, 2012 to assess feasibility of recruitment
of patients with DMD. A comparison of recruited DMD patients
was made to expected cases calculated from available
prevalence estimates and population statistics for Canadian
males aged 5- 24. Each participating paediatric NMC was
attributed a proportion of each province’s overall calculated
cases based on relative catchment area populations from the
2010 census. The target enrollment for each clinic was then
based upon the expected number of cases at that clinic based on
the resulting formula (target number of DMD cases = population
at risk (males between and including ages 5-24 years) x
prevalence x proportion of population within the clinic’s
catchment area). A minimum recruitment proportion exceeding
20% of expected DMD patients in the majority of included
clinics was established as the feasibility criterion based upon
timing of NMCs beginning recruitment, patient return-to-clinic
intervals and physician availability for recruitment during clinic
visits.
RESULTS

The CNDR began patient enrollment in September 2010 with
enrollment into the feasibility phase beginning March 2011 and
a formal launch in June 2011.

Neuromuscular Clinic Recruitment

As of December 2012, the CNDR is comprised of twenty
clinical sites in eleven academic centres (see Table 1).
At each clinic between one and four site co-principal
investigators comprised of adult and paediatric neurologists and
physiatrists participate in the CNDR.

Recruitment Feasibility Case Studies

The first case study examined ALS patient recruitment in the
Calgary ALS Clinic. Eighty patients were identified and
contacted with 68 patients providing signed informed consent
for a capture proportion of 85%. One patient declined enrollment

LE JOURNAL CANADIEN DES SCIENCES NEUROLOGIQUES

Table 1: Adult and paediatric neuromuscular clinics participating in the CNDR
CITY
Vancouver, BC
Calgary, AB

Edmonton, AB
Mississauga, ON
Toronto, ON
London, ON
Ottawa, ON

Kingston, ON

Montreal, QC
Halifax, NS
Fredericton, NB

•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•

CLINICAL SITES
Vancouver General Hospital
BC Children’s Hospital
Foothills Hospital
South Health Campus
Alberta Children’s Hospital
University Hospital
ErinoakKids Centre for Treatment &
Development
University Health Network
Holland Bloorview Kids Rehabilitation Hospital
London Health Sciences Centre
Thames Valley Children’s Centre
Ottawa Hospital Rehabilitation Centre
Ottawa Hospital Civic Campus
Children’s Hospital of Eastern Ontario
Kingston General Hospital
Child Development Centre, Hotel Dieu Hospital
Providence Care – St. Mary’s of the Lake
Montreal Neurological Institute
Halifax Infirmary
IWK Health Centre
Stan Cassidy Centre for Rehabilitation

with the remaining patients being undecided, deceased or lost to
follow up. It was felt that the high capture proportion
demonstrated feasibility of ALS subject recruitment through a
clinic-based registry design. It is expected that near or complete
case ascertainment is achievable via in-clinic, telephone and
mail-out patient contact.
The second case study examined DMD recruitment across
five paediatric clinics (see Table 2). We used a previously
published minimum prevalence estimate of 1.3/10,000 males
aged 5 – 2419 based on data from four US states which is
supported by Canadian findings of 1.5/10,000 males aged 0 – 24

ACADEMIC INSTITUTION
University of British Columbia
University of Calgary

University of Alberta
McMaster University
University of Toronto
Western University
University of Ottawa

Queen’s University

McGill University
Dalhousie University
University of New Brunswick/Dalhousie University

based on dystrophin mutation analysis6. The CNDR has set the
goal of complete ascertainment of this lower incidence estimate
in its clinics by March 31, 2013. During the recruitment interval
217 patients with DMD were recruited in the five clinics
comprising 112.4% of the March 2013 population-based
recruitment target of 193 patients.

Overall Recruitment

To date the CNDR has recruited 1161 patients from twelve of
the thirteen provinces and territories while having clinics in only
6 provinces (see Table 3). Of the 1161 patients, 543 (47%) are

Table 2: Projected DMD recruitment targets in CNDR clinics and actual recruitment
Province

Alberta
British
Columbia
Ontario

TOTAL

Male population
age 5 - 24 (as of
July 1, 2010 –
Statistics
Canada)
496,657
554,042

Minimum
Prevalence
Estimate
(1.3/10,000
males)
65
72

Estimated pediatric
clinic capture (% of
provincial total)

DMD
Population
Target (March
31, 2013)

Actual
Recruitment
(December
31, 2012)

Calgary – 56.41%
Vancouver – 100%*

37
72

29
56

1,692,014

220

London – 7.60%

17

50

294.1%

Ottawa – 9.37%

21

25

119.0%

Mississauga – 8.67%

19

9

47.4%

Toronto - 8.60%

19

35

184.2%

Kingston – 3.57%

8

13

162.5%

46%

193

217**

112.4%

2,742,713

357

Proportion
Recruited
(Between March
2011 and
December 2012)
78.4%
77.8%

*only neuromuscular clinic in the province; **one DMD patient was recruited through the national office for a
total of 218 patients.
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Table 3: Subjects recruited as of December 31, 2012 by disease
Index Disease
Duchenne muscular dystrophy

Number of Subjects
218

Non-Index Disease
ALS

Number of Subjects
108

Becker muscular dystrophy

35

Myasthenia gravis (all types)
Charcot-Marie Tooth (all types)
Spinal muscular atrophy

61
54

Intermediate dystrophinopathy

4

Limb-girdle muscular dystrophy (all types)

52
47

Manifesting female
dystrophinopathy carriers

7

Myotonic muscular dystrophy
(type 1 and 2)

161

Facioscapulohumeral muscular dystrophy

46

Guillain-Barré syndrome

21

ALS

57

Inclusion body myositis
Oculopharyngeal muscular dystrophy

21

Incomplete

40

Primary lateral sclerosis

16
15

Total Index

543

Total Subjects

1161

index disease patients with 218 being DMD, and 161 DM. The
other index diseases include Becker muscular dystrophy,
Intermediate muscular dystrophy, ALS, and Guillain-Barré
syndrome. The remaining 618 patients are “non-index” patients
representing over 20 neuromuscular conditions. In 2012, ALS
was added as an index disease transitioning from the non-index
group and some patients are still in the process of being reconsented. In 2013, the CNDR will transition SMA from the
non-index group to the index group. The largest non-index
populations are: ALS (108), myasthenia gravis (61), CharcotMarie Tooth (54), SMA (52), limb girdle muscular dystrophy
(47) and FSHD (46) patients. Within the next two years the
CNDR aims to recruit 4000 patients across Canada.

Facilitating Clinical Research

Through December 31, 2012, the CNDR provided deidentified data for two clinical trial feasibility requests approved
by the TREAT-NMD Alliance. The CNDR has notified patients
for two peer-reviewed academically funded studies, and a third
study was recently approved. In one study examining NMD and
occupational status 189 information letters were mailed to adult
patients. For the second study, 639 information letters were
mailed to adults and parents of children age 5-16 with chronic
neurologic diseases for a large cross sectional quality of life
study. The CNDR has also facilitated site selection for one
additional pharmaceutical industry inquiry and provided deidentified statistical information for three additional investigator
or industry initiated inquiries. This is a total of nine inquiries
since June 2011.
CONCLUSIONS
The CNDR is a Canada-wide registry of patients with
neuromuscular disease. Using an innovative approach to
organization of patient information through a blended patient
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Chronic inflammatory demyelinating
polyneuropathy
All other diseases
Total Non-Index

15
183
618

recruitment model, the CNDR has enrolled patients from 12
provinces and territories. The CNDR is providing access to data
through a rigorous peer-review process to maximize availability
of the data to the international research community and is a new
data source for examining potential disparities between
provincial health care systems. Through accurate and
comprehensive prospective data collection the CNDR is
anticipated to facilitate clinical research, expedite clinical trials,
and provide important epidemiological insights while improving
access to novel therapies for Canadians with NMD.
Sustainability

The CNDR has been funded through contributions from the
ALS Society of Canada (Toronto, Ontario), the Families of
Spinal Muscular Atrophy Canada Society (Chilliwack, British
Columbia), Jesse’s Journey (London, Ontario) and the Marigold
Foundation (Calgary, Alberta) as well as individual private
donations. The single infrastructure, multi-disease model permits
sponsor cost-sharing for central operating costs and direct
allocation of disease-specific funds to specific NMCs for data
entry. Alternative data entry technology is currently being
examined to enhance data entry quality and reduce cost. To date,
members of the CNDR Investigator Network have applied for
five research grants to fund national level multi-centered NMD
research projects using the CNDR infrastructure for data
collection with appropriate CNDR-allocated budget incorporated into each submission. Pharmaceutical company
inquiries will be provided data for clinical trial planning and
recruitment on a cost-recovery basis. The CNDR will also be
examined as a Phase IV post-approval monitoring tool. The
combination of these strategies is expected to result in a
sustainable operating budget in the long term.

LE JOURNAL CANADIEN DES SCIENCES NEUROLOGIQUES

Limitations

Patient registries provide the most generalizable
epidemiological and outcome data when case ascertainment is
complete. Registry data that are not population-based increase
the risk of recruitment bias and study findings not representing
the overall affected population. Other clear limitations to registry
methodology include the time and financial burdens associated
with informed consent requirements which are an essential
component of conducting clinical research. At this time, the
CNDR does not include all Canadian NMCs and as a result
patients will not be uniformly recruited across Canada. While the
ultimate aim of the CNDR is to evolve into a national
population-based registry with complete ascertainment of
patients with specific index NMDs, the initial goal is to
demonstrate complete ascertainment in multiple provinces
beginning in 2013. The limited number of NMCs in provinces
such as Nova Scotia (2) and British Columbia (2) suggest this
goal is realistic. Data linkage to administrative sources and
validation of population-based status will be pursued.
The CNDR is a highly collaborative network of investigators,
actively engaged with non-profit and charitable organizations as
sponsors, sharing a vision of improving the lives of those with
NMD in Canada.
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APPENDIX I*

The CNDR Investigator Network is comprised of all investigators who have contributed time and expertise in developing the
CNDR protocol, data sets and/or documentation.

National Principal Investigator - Lawrence Korngut (University of Calgary); National Project Manager - Megan Johnston
(University of Calgary); Advisory Committee - Craig Campbell (Paediatric Expert; Western University), Timothy Benstead
(Adult Expert; Dalhousie University), Angela Genge (ALS Expert; McGill University), Alex MacKenzie (SMA Expert,
University of Ottawa), Anna McCormick (DMD expert; University of Ottawa); Site Co-Principal Investigators - Timothy
Benstead (Dalhousie University), Douglas Biggar (Holland Bloorview Kids Rehabilitation Hospital, University of Toronto),
Pierre Bourque (University of Ottawa), Hannah Briemberg (University of British Columbia), Vera Bril (University of Toronto),
Craig Campbell (Western University), Alan Casey (University of Manitoba), Neil Cashman (University of British Columbia),
Kristine Chapman (University of British Columbia), Colleen O’Connell (Stan Cassidy Centre for Rehabilitation), Suzan Dojeiji
(University of Ottawa), Joseph Dooley (Dalhousie University), Nicolas Dupre (Laval University), Gillian Gibson (University of
British Columbia), Ian Grant (Dalhousie University), Walter Hader (University of Saskatchewan), Gillian Hogan (ErinoakKids
Centre for Treatment and Development), Wendy Johnston (University of Alberta), Sanjay Kalra (University of Alberta), Hans D.
Katzberg (University of Toronto), Charles Krieger (University of British Columbia), Edward Leung (University of Manitoba),
Jean K. Mah (University of Calgary), Laura McAdam (Holland Bloorview Kids Rehabilitation Hospital, University of Toronto),
Anna McCormick (University of Ottawa), Hugh McMillan (University of Ottawa), Michel Melanson (Queen’s University),
Michelle M. Mezei (University of British Columbia), Kerri Schellenberg (University of Alberta), Kathryn Selby (University of
British Columbia), Christen Shoesmith (Western University), Garth Smith (Queen’s University), Shannon L. Venance (Western
University), Joy Wee (Queen’s University), Scott Worley (Stan Cassidy Centre for Rehabilitation, Dalhousie University), Lorne
Zinman (University of Toronto). DMD Working Group - Craig Campbell (Paediatric Expert; University of Western Ontario),
Gillian Hogan (Working Group Member, ErinoakKids Centre for Treatment and Development), Jean K. Mah (Working Group
Member, University of Calgary), Laura McAdam (Working Group Member, Holland Bloorview Kids Rehabilitation Hospital),
Anna McCormick (Working Group Lead, University of Ottawa) Peter Ray (DMD Genetics Expert, University of Toronto),
Kathryn Selby (Working Group Member, University of British Columbia), ALS Working Group - Colleen O’Connell
(University of New Brunswick), Angela Genge (Working Group Lead; McGill University), Christen Shoesmith (University of
Western Ontario), SMA Working Group - Craig Campbell (Paediatric Expert; University of Western Ontario), Alex MacKenzie
(Working Group Lead, University of Ottawa), Maryam Oskoui (Working Group Member; McGill University), Kathryn Selby
(Working Group Member, University of British Columbia), Louise Simard (Working Group Member, University of Manitoba),
Jiri Vajsar (Working Group Member, University of Toronto).

APPENDIX II

Data is entered through a secure portal interface accessible from any desktop computer with Internet access and then sent via
secure socket layer (SSL) transmission over the Internet to a secure data server housed at the University of Calgary. Local data
collection forms are maintained as source documents for review at annual audit visits by CNDR National Office staff. Specific
requirements for individual dataset fields are outlined in data reference manuals. Data entry is reviewed weekly at the National
Office to ensure data standard compliance. Detected errors are logged and reported to site data-entry personnel for correction.
Data entry personnel have the opportunity to attend semi-monthly data support teleconferences with CNDR National Office staff
to troubleshoot common problems and discuss data entry anomalies noted at the national office enhancing future data entry
quality. Regular data audits will be performed beginning in mid-2012.
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